問卷

TPIDB > Principal Investigator

Principal Investigator


Koo Foundation Sun Yat-Sen Cancer Center (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

鍾奇峰
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

90Cases

2025-06-30 - 2028-12-31

Phase I

Not yet recruiting
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
  • Condition/Disease

    Recurrent or Metastatic Solid Tumors

  • Test Drug

    Frozen crystal powder and liquid for injection

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2030-05-18

Phase III

Not yet recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01) Conditions
  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    Frozen crystal powder for injection Intravenous infusion solution Infusion solution Infusion solution Concentrated powder Infusion solution

Participate Sites
8Sites

Recruiting8Sites

2009-08-30 - 2014-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2009-06-01 - 2014-03-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2025-02-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2019-11-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2013-05-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-03-06 - 2030-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites